ACADIA Pharmaceuticals (NASDAQ:ACAD) Releases Earnings Results, Beats Expectations By $0.11 EPS

ACADIA Pharmaceuticals (NASDAQ:ACAD) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.11, FiscalAI reports. The firm had revenue of $342.30 million during the quarter, compared to analysts’ expectations of $332.58 million. ACADIA Pharmaceuticals had a net margin of 30.13% and a return on equity of 9.12%. The company’s revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.42 earnings per share.

Here are the key takeaways from ACADIA Pharmaceuticals’ conference call:

• ACADIA reported $342 million in Q3 revenue, up 22% year over year on an adjusted basis. DAYBUE sales reached a record $140 million, up 39%, while NUPLAZID generated $202 million, up 12%; growth for both brands was largely volume-driven.
• ACADIA raised its 2026 DAYBUE sales guidance to $505 million–$520 million, citing STIX momentum, with more than half of U.S. patients using the formulation by quarter-end. The company also highlighted its Germany launch and a newly allowed U.S. patent expected to protect both formulations through March 2041, while reiterating its $700 million sales ambition for 2028.
• NUPLAZID guidance was narrowed to $760 million–$775 million, with management citing the time needed for its expanded sales force to build prescribing relationships. ACADIA maintained its ambition of approximately $1 billion in NUPLAZID sales by the end of 2028.
• The phase II RADIANT trial of remlifanserin in Alzheimer’s disease psychosis narrowly missed statistical significance on its primary endpoint (p=0.0603), although the 60 mg dose showed activity across four efficacy scales and a nominally significant result on a key secondary endpoint. ACADIA plans to advance the 60 mg dose and adjust trial conduct and statistical methods for phase III; the primary endpoint remains unchanged.
• ACADIA expects phase II results for remlifanserin in Lewy body dementia psychosis and for ACP-211 in major depressive disorder in the second half of 2027, extending the timeline for pipeline updates. The company ended the quarter with $976 million in cash.

ACADIA Pharmaceuticals Trading Up 0.1%

Shares of NASDAQ:ACAD traded up $0.02 during midday trading on Friday, reaching $21.26. 798,741 shares of the company were exchanged, compared to its average volume of 1,746,874. The business’s fifty day moving average is $23.03 and its two-hundred day moving average is $23.62. ACADIA Pharmaceuticals has a one year low of $18.39 and a one year high of $30.96. The stock has a market cap of $3.66 billion, a PE ratio of 10.08 and a beta of 0.87.

Analyst Upgrades and Downgrades

ACAD has been the subject of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $35.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Monday, October 19th. TD Cowen reissued a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, September 24th. Citizens Jmp reduced their price objective on shares of ACADIA Pharmaceuticals from $36.00 to $33.00 and set a “market outperform” rating for the company in a research note on Friday, September 25th. UBS Group cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $49.00 to $23.00 in a research note on Tuesday, October 13th. Finally, HC Wainwright reduced their price objective on shares of ACADIA Pharmaceuticals from $37.00 to $33.00 and set a “buy” rating for the company in a research note on Friday, September 25th. Thirteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $31.45.

Insider Buying and Selling at ACADIA Pharmaceuticals

In related news, EVP Mark Schneyer sold 3,321 shares of the company’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $20.88, for a total transaction of $69,342.48. Following the completion of the transaction, the executive vice president owned 71,322 shares in the company, valued at approximately $1,489,203.36. This represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system and neuropsychiatric disorders. The company’s research programs target conditions with significant unmet medical needs, including neurological and rare neurodevelopmental diseases.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis.